Sanofi halts development of amlitelimab for atopic dermatitis, citing limited improvement over current treatments.

Sanofi has decided to stop the clinical development of amlitelimab, a monoclonal antibody for moderate-to-severe atopic dermatitis (AD), after reviewing its efficacy and safety data. Despite positive long-term results from the ESTUARY phase 3 study, the drug does not offer a meaningful improvement over existing treatments. Sanofi will wind down ongoing studies and ensure patient care transitions smoothly. The company remains committed to advancing treatments for inflammatory skin conditions and will present further study results at a future medical meeting.